Archives: 2023-11-14

PIER MARIA FORNASARI
2023-11-14

Ground-breaking discovery could pave the way for new therapies to prevent cardiovascular disease and stroke

Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our diet is absorbed into our cells. This discovery, which has just been published in the journal Science opens up new opportunities for therapeutic intervention to control cholesterol uptake that could complement other therapies and potentially save lives. The research, conducted with colleagues

Read More

No Comments InRESEARCH WELLNESS
PIER MARIA FORNASARI
2023-11-14

Bioactive, 3D-Printed Composite Material Supports Broken Bone Healing

A broken bone failing to heal represents an enormous burden for patients, which also often leads to further additional surgeries being required. Fraunhofer researchers have worked alongside partners to develop a composite material to be used in the treatment of such non-union cases. The resulting implant (termed scaffold) is designed to significantly improve treatment success

Read More

No Comments InBIOPRINTING
PIER MARIA FORNASARI
2023-11-13

VERVE-101: CRISPR-Based Gene Editing Therapy Shows Promise in Reducing LDL-C and PCSK9 Levels in Patients With HeFH

A single infusion of a CRISPR-based gene editing therapy significantly reduced LDL-C and PCSK9 levels in patients with heterozygous familial hypercholesterolemia (HeFH), based on findings from the VERVE-101 trial presented Nov. 12 at AHA 2023. In presenting the findings, Andrew Bellinger, MD, PhD, said they provide the first proof-of-concept for in vivo DNA base editing in humans.

Read More

No Comments InGENE EDITING
PIER MARIA FORNASARI
2023-11-13

Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events

Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine At the American Heart Asoociation annual Scientific Session were announced the primary results of SELECT, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4 mg (Wegovy®) in

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2023-11-10

COVID Moonshot Consortium Unveils Crowd-Sourced Covid Antiviral Lead Compound

The work of the COVID Moonshot Consortium is being published in the prestigious journal Science on 10 November, revealing their discovery of a potent SARS-CoV-2 antiviral lead compound. It also reflects on the success of its open science approach in launching a patent-free antiviral discovery program to rapidly develop a differentiated lead in response to

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2023-11-10

FDA Approves First Treatment for Patients with Rare Congenital Thrombotic Thrombocytopenic Purpura

The U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains deeply committed in our efforts to help facilitate

Read More

No Comments InRARE DISEASES
PIER MARIA FORNASARI
2023-11-10

November the 10th Updated living WHO guideline on drugs for covid-19

November the 10th a panel of international experts representing the World Health Organization’s Guideline Development Group has updated its guidance on treatments for patients with COVID-19. The new recommendations published by The BMJ are part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide up

Read More

No Comments InCovid-19